Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Abstract Background Risperidone ISM® is a newly developed long-acting injectable (LAI) treatment for schizophrenia in adults. In the absence of head-to-head comparisons with other similar antipsychotics, the objective of this study was to generate indirect evidence of some aspects of the safety and...

Description complète

Détails bibliographiques
Auteurs principaux: Pedro Sánchez, Cecilio Álamo, Marcos Almendros, Max Schlueter, Anastasios Tasoulas, Javier Martínez
Format: Article
Langue:English
Publié: BMC 2023-09-01
Collection:Annals of General Psychiatry
Sujets:
Schizophrenia
Risperidone
Matching-adjusted indirect comparison
MAIC
Extrapyramidal symptom
Anticholinergics
Accès en ligne:https://doi.org/10.1186/s12991-023-00464-z

Internet

https://doi.org/10.1186/s12991-023-00464-z

Documents similaires